The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bischof, O., Nacerddine, K., & Dejean, A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.3.1013-1024.2005 · Cited by 84
RetractedLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
de Thé, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990) · Nature · doi:10.1038/347558a0 · Cited by 1,355
Self-citationde Thé, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L., & Dejean, A. (1991) · Cell · doi:10.1016/0092-8674(91)90113-d · Cited by 1,343
Self-citationAcute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
Self-citationSanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Chen, G., Zhu, J., Shi, X., Ni, J., Zhong, H., Si, G., Jin, X., Tang, W., Li, X., Xong, S., et al. (1996) · Blood · doi:10.1182/blood.v88.3.1052.1052 · Cited by 864
Self-citationLenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras
Pearson, M., Carbone, R., Sebastiani, C., Cioce, M., Fagioli, M., Saito, S., Higashimoto, Y., Appella, E., Minucci, S., Pandolfi, P. P., et al. (2000) · Nature · doi:10.1038/35018127 · Cited by 847
Self-citationArsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML
Zhang, X.-W., Yan, X.-J., Zhou, Z.-R., Yang, F.-F., Wu, Z.-Y., Sun, H.-B., Liang, W.-X., Song, A.-X., Lallemand-Breitenbach, V., Jeanne, M., et al. (2010) · Science · doi:10.1126/science.1183424 · Cited by 785
Self-citationChen, G., Shi, X., Tang, W., Xiong, S. M., Zhu, J., Cai, X., Han, Z., Ni, J.-H., Shi, G., Jia, P.-M., et al. (1997) · PubMed · Cited by 781
Self-citationNon-Cell-Autonomous Tumor Suppression by p53
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766 · cited 1×
“In mouse models, senescence seems implicated in APL clearance, and the immune system is critically important to eliminate senescent cells (Ablain et al., 2014; Korf et al., 2014; Lujambio et al., 2013; Nardella et al., 2011).”
BackgroundArsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway
Lallemand-Breitenbach, V., Jeanne, M., Benhenda, S., Nasr, R., Lei, M., Peres, L., Zhou, J., Zhu, J., Raught, B., & de Thé, H. (2008) · Nature Cell Biology · doi:10.1038/ncb1717 · Cited by 734
Self-citationMuller, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.1.61 · Cited by 674
Chen, Z., Brand, N. J., Chen, A., Chen, S. J., Tong, J. H., Wang, Z. Y., Waxman, S., & Zelent, A. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05757.x · Cited by 640
Self-citation15/17 TRANSLOCATION, A CONSISTENT CHROMOSOMAL CHANGE IN ACUTE PROMYELOCYTIC LEUKAEMIA
Rowley, J., Golomb, H., & Dougherty, C. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91415-5 · Cited by 633
Niu, C., Yan, H., Yu, T., Sun, H.-P., Liu, J.-X., Li, X.-S., Wu, W., Zhang, F.-Q., Chen, Y., Zhou, L., et al. (1999) · Blood · doi:10.1182/blood.v94.10.3315.422k16_3315_3324 · Cited by 625
Self-citationStructural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620
Shen, Z.-X., Shi, Z.-Z., Fang, J., Gu, B.-W., Li, J.-M., Zhu, Y.-M., Shi, J.-Y., Zheng, P.-Z., Yan, H., Liu, Y.-F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400053101 · Cited by 583
Self-citationThe Role of PML in Tumor Suppression
Salomoni, P., & Pandolfi, P. P. (2002) · Cell · doi:10.1016/s0092-8674(02)00626-8 · Cited by 566
Self-citationLallemand-Breitenbach, V., & de The, H. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000661 · Cited by 563
PML targeting eradicates quiescent leukaemia-initiating cells
Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., Rosenblatt, J., Avigan, D. E., Teruya-Feldstein, J., & Pandolfi, P. P. (2008) · Nature · doi:10.1038/nature07016 · Cited by 538
Self-citationBurnett, A. K., Russell, N. H., Hills, R. K., Bowen, D., Kell, J., Knapper, S., Morgan, Y. G., Lok, J., Grech, A., Jones, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00193-x · Cited by 534
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure
de Thé, H., & Chen, Z. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2943 · Cited by 488
Self-citationLallemand-Breitenbach, V., Zhu, J., Puvion, F., Koken, M., Honoré, N., Doubeikovsky, A., Duprez, E., Pandolfi, P. P., Puvion, E., Freemont, P., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.12.1361 · Cited by 488
Self-citationThe function of PML in p53-dependent apoptosis
Guo, A., Salomoni, P., Luo, J., Shih, A., Zhong, S., Gu, W., & Paolo Pandolfi, P. (2000) · Nature Cell Biology · doi:10.1038/35036365 · Cited by 472
Pro-senescence therapy for cancer treatment
Nardella, C., Clohessy, J. G., Alimonti, A., & Pandolfi, P. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3057 · Cited by 437
Self-citationZhu, J., Koken, M. H. M., Quignon, F., Chelbi-Alix, M. K., Degos, L., Wang, Z. Y., Chen, Z., & de Thé, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3978 · Cited by 427
Self-citationHu, J., Liu, Y.-F., Wu, C.-F., Xu, F., Shen, Z.-X., Zhu, Y.-M., Li, J.-M., Tang, W., Zhao, W.-L., Wu, W., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813280106 · Cited by 425
Self-citationMORTALITY IN ORAL CONTRACEPTIVE USERS
VESSEY, M. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92875-0 · Cited by 394
Platzbecker, U., Avvisati, G., Cicconi, L., Thiede, C., Paoloni, F., Vignetti, M., Ferrara, F., Divona, M., Albano, F., Efficace, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1982 · Cited by 389
Estey, E., Garcia-Manero, G., Ferrajoli, A., Faderl, S., Verstovsek, S., Jones, D., & Kantarjian, H. (2006) · Blood · doi:10.1182/blood-2005-10-4006 · Cited by 384
Zhu, J., Gianni, M., Kopf, E., Honoré, N., Chelbi-Alix, M., Koken, M., Quignon, F., Rochette-Egly, C., & de Thé, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14807 · Cited by 372
Self-citationDegos, L., Dombret, H., Chomienne, C., Daniel, M., Miclea, J., Chastang, C., Castaigne, S., & Fenaux, P. (1995) · Blood · doi:10.1182/blood.v85.10.2643.bloodjournal85102643 · Cited by 362
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
Nasr, R., Guillemin, M.-C., Ferhi, O., Soilihi, H., Peres, L., Berthier, C., Rousselot, P., Robledo-Sarmiento, M., Lallemand-Breitenbach, V., Gourmel, B., et al. (2008) · Nature Medicine · doi:10.1038/nm.1891 · Cited by 354
Self-citationShao, W., Fanelli, M., Ferrara, F. F., Riccioni, R., Rosenauer, A., Davison, K., Lamph, W. W., Waxman, S., Pelicci, P. G., Lo Coco, F., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.2.124 · Cited by 344
PML/RARA Oxidation and Arsenic Binding Initiate the Antileukemia Response of As2O3
Jeanne, M., Lallemand-Breitenbach, V., Ferhi, O., Koken, M., Le Bras, M., Duffort, S., Peres, L., Berthier, C., Soilihi, H., Raught, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.003 · Cited by 335
Self-citationLoss of the Tumor Suppressor PML in Human Cancers of Multiple Histologic Origins
Gurrieri, C., Capodieci, P., Bernardi, R., Scaglioni, P. P., Nafa, K., Rush, L. J., Verbel, D. A., Cordon-Cardo, C., & Pandolfi, P. P. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh043 · Cited by 334
Self-citationLallemand-Breitenbach, V., Guillemin, M.-C., Janin, A., Daniel, M.-T., Degos, L., Kogan, S. C., Michael Bishop, J., & de Thé, H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.7.1043 · Cited by 305
Self-citationA CK2-Dependent Mechanism for Degradation of the PML Tumor Suppressor
Scaglioni, P. P., Yung, T. M., Cai, L. F., Erdjument-Bromage, H., Kaufman, A. J., Singh, B., Teruya-Feldstein, J., Tempst, P., & Pandolfi, P. P. (2006) · Cell · doi:10.1016/j.cell.2006.05.041 · Cited by 295
Self-citationAbaza, Y., Kantarjian, H., Garcia-Manero, G., Estey, E., Borthakur, G., Jabbour, E., Faderl, S., O’Brien, S., Wierda, W., Pierce, S., et al. (2017) · Blood · doi:10.1182/blood-2016-09-736686 · Cited by 286
Oligomerization of RAR and AML1 Transcription Factors as a Novel Mechanism of Oncogenic Activation
Minucci, S., Maccarana, M., Cioce, M., De Luca, P., Gelmetti, V., Segalla, S., Di Croce, L., Giavara, S., Matteucci, C., Gobbi, A., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80321-4 · Cited by 285
Wei, S., Kozono, S., Kats, L., Nechama, M., Li, W., Guarnerio, J., Luo, M., You, M.-H., Yao, Y., Kondo, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3839 · Cited by 272
Self-citationA metabolic prosurvival role for PML in breast cancer
Carracedo, A., Weiss, D., Leliaert, A. K., Bhasin, M., de Boer, V. C. J., Laurent, G., Adams, A. C., Sundvall, M., Song, S. J., Ito, K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62129 · Cited by 269
Self-citationStadler, M., Chelbi‐Alix, M. K., Koken, M. H. M., Venturini, L., Lee, C., Saı̈b, A., Quignon, F., Pelicano, L., Guillemin, M.-C., & Schindler, C. (1995) · PubMed · Cited by 266
Mathews, V., George, B., Chendamarai, E., Lakshmi, K. M., Desire, S., Balasubramanian, P., Viswabandya, A., Thirugnanam, R., Abraham, A., Shaji, R. V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5031 · Cited by 252
PML protein expression in hematopoietic and acute promyelocytic leukemia cells
Daniel, M., Koken, M., Romagne, O., Barbey, S., Bazarbachi, A., Stadler, M., Guillemin, M., Degos, L., Chomienne, C., & de The, H. (1993) · Blood · doi:10.1182/blood.v82.6.1858.1858 · Cited by 251
The PML growth-suppressor has an altered expression in human oncogenesis.
Koken, M. H. M., Linares‐Cruz, G., Quignon, F., Viron, A., Chelbi‐Alix, M. K., Sobczak‐Thépot, J., Juhlin, L., Degos, L., Calvo, F. M., & de Thé, H. (1995) · PubMed · Cited by 231
Modern Approaches to Treating Acute Promyelocytic Leukemia
Sanz, M. A., & Lo-Coco, F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.1067 · Cited by 220
Ghavamzadeh, A., Alimoghaddam, K., Rostami, S., Ghaffari, S. H., Jahani, M., Iravani, M., Mousavi, S. A., Bahar, B., & Jalili, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2107 · Cited by 214
Acute promyelocytic leukemia, arsenic, and PML bodies
de Thé, H., Le Bras, M., & Lallemand-Breitenbach, V. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201112044 · Cited by 213
Self-citationJing, Y., Wang, L., Xia, L., Chen, G.-Q., Chen, Z., Miller, W. H., & Waxman, S. (2001) · Blood · doi:10.1182/blood.v97.1.264 · Cited by 204
Self-citationKchour, G., Tarhini, M., Kooshyar, M.-M., El Hajj, H., Wattel, E., Mahmoudi, M., Hatoum, H., Rahimi, H., Maleki, M., Rafatpanah, H., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211821 · Cited by 199
Self-citationRego, E. M., He, L.-Z., Warrell, R. P., Wang, Z.-G., & Pandolfi, P. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180290497 · Cited by 194
Self-citationAblain, J., Rice, K., Soilihi, H., de Reynies, A., Minucci, S., & de Thé, H. (2014) · Nature Medicine · doi:10.1038/nm.3441 · Cited by 191
Self-citationYuan, W.-C., Lee, Y.-R., Huang, S.-F., Lin, Y.-M., Chen, T.-Y., Chung, H.-C., Tsai, C.-H., Chen, H.-Y., Chiang, C.-T., Lai, C.-K., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.008 · Cited by 184
Zhu, H.-H., Wu, D.-P., Jin, J., Li, J.-Y., Ma, J., Wang, J.-X., Jiang, H., Chen, S.-J., & Huang, X.-J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.8312 · Cited by 181
Regulation of E2Fs and senescence by PML nuclear bodies
Vernier, M., Bourdeau, V., Gaumont-Leclerc, M.-F., Moiseeva, O., Bégin, V., Saad, F., Mes-Masson, A.-M., & Ferbeyre, G. (2011) · Genes & Development · doi:10.1101/gad.1975111 · Cited by 177
Camacho, L. H., Soignet, S. L., Chanel, S., Ho, R., Heller, G., Scheinberg, D. A., Ellison, R., & Warrell, R. P. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2620 · Cited by 174
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal
Zhao, Z., Zuber, J., Diaz-Flores, E., Lintault, L., Kogan, S. C., Shannon, K., & Lowe, S. W. (2010) · Genes & Development · doi:10.1101/gad.1940710 · Cited by 166
Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression
Rego, E. M., Wang, Z.-G., Peruzzi, D., He, L.-Z., Cordon-Cardo, C., & Pandolfi, P. P. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.4.521 · Cited by 161
Self-citationZhu, J., Lallemand-Breitenbach, V., & de Thé, H. (2001) · Oncogene · doi:10.1038/sj.onc.1204852 · Cited by 152
dos Santos, G. A., Kats, L. M., & Pandolfi, P. P. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131121 · Cited by 152
Self-citationTwo Critical Hits for Promyelocytic Leukemia
He, L.-Z., Bhaumik, M., Tribioli, C., Rego, E. M., Ivins, S. M., Zelent, A., & Pandolfi, P. P. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00111-8 · Cited by 143
Self-citationMartelli, M. P., Gionfriddo, I., Mezzasoma, F., Milano, F., Pierangeli, S., Mulas, F., Pacini, R., Tabarrini, A., Pettirossi, V., Rossi, R., et al. (2015) · Blood · doi:10.1182/blood-2014-11-611459 · Cited by 139
El-Sabban, M. E., Nasr, R., Dbaibo, G. S., Hermine, O., Abboushi, N., Quignon, F., Ameisen, J., Bex, F., de Thé, H., & Bazarbachi, A. A. (2000) · PubMed · doi:10.1182/blood.v96.8.2849 · Cited by 139
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
Madan, V., Shyamsunder, P., Han, L., Mayakonda, A., Nagata, Y., Sundaresan, J., Kanojia, D., Yoshida, K., Ganesan, S., Hattori, N., et al. (2016) · Leukemia · doi:10.1038/leu.2016.69 · Cited by 137
Nilsson, B. (1984) · British Journal of Haematology · doi:10.1111/j.1365-2141.1984.tb02910.x · Cited by 132
Hajj, H. E., Dassouki, Z., Berthier, C., Raffoux, E., Adès, L., Legrand, O., Hleihel, R., Şahin, U., Tawil, N., Salameh, A., et al. (2015) · Blood · doi:10.1182/blood-2014-11-612416 · Cited by 130
Impairment of p53 acetylation, stability and function by an oncogenic transcription factor
Insinga, A., Monestiroli, S., Ronzoni, S., Carbone, R., Pearson, M. A., Pruneri, G., Viale, G., Appella, E., Pelicci, P. G., & Minucci, S. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600109 · Cited by 130
Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia
Zhu, H., Qin, Y.-Z., & Huang, X. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1316382 · Cited by 126
The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
Rabellino, A., Carter, B., Konstantinidou, G., Wu, S.-Y., Rimessi, A., Byers, L. A., Heymach, J. V., Girard, L., Chiang, C., Teruya‐Feldstein, J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3159 · Cited by 122
Goto, E., Tomita, A., Hayakawa, F., Atsumi, A., Kiyoi, H., & Naoe, T. (2011) · Blood · doi:10.1182/blood-2011-01-329433 · Cited by 119
Mantha, S. H., Goldman, D. A., Devlin, S. M., Lee, J., Zannino, D., Collins, M. L., Douer, D., Iland, H. J., Litzow, M. R., Stein, E. M., et al. (2017) · Blood · doi:10.1182/blood-2016-10-747170 · Cited by 116
Li, K., Wang, F., Cao, W., Lv, X., Hua, F., Cui, B., Yu, J., Zhang, X., Shang, S., Liu, S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.006 · Cited by 112
USP11 regulates PML stability to control Notch-induced malignancy in brain tumours
Wu, H.-C., Lin, Y., Liu, C., Chung, H.-C., Wang, Y., Lin, Y., Ma, H., Tu, P., Lawler, S. E., & Chen, R. (2014) · Nature Communications · doi:10.1038/ncomms4214 · Cited by 111
Vickers, M. A., Jackson, G. H., & Taylor, P. R. A. (2000) · Leukemia · doi:10.1038/sj.leu.2401722 · Cited by 110
How Much Longer Will We Put Up With $100,000 Cancer Drugs?
Workman, P., Draetta, G. F., Schellens, J. H. M., & Bernards, R. (2017) · Cell · doi:10.1016/j.cell.2017.01.034 · Cited by 109
PML is a ROS sensor activating p53 upon oxidative stress
Niwa-Kawakita, M., Ferhi, O., Soilihi, H., Le Bras, M., Lallemand-Breitenbach, V., & de Thé, H. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160301 · Cited by 104
Du, C., Redner, R. L., Cooke, M. P., & Lavau, C. (1999) · Blood · doi:10.1182/blood.v94.2.793 · Cited by 102
Oral Arsenic and Retinoic Acid for Non–High-Risk Acute Promyelocytic Leukemia
Zhu, H., & Huang, X. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1412035 · Cited by 102
Koken, M. H. M., Daniel, M., Gianni’, M., Zelent, A., Licht, J. D., Buzyn, A., Minard, P., Degos, L., Varet, B. R., & de Thé, H. (1999) · Oncogene · doi:10.1038/sj.onc.1202414 · Cited by 100
Guillemin, M.-C., Raffoux, E., Vitoux, D., Kogan, S. C., Soilihi, H., Lallemand-Breitenbach, V., Zhu, J., Janin, A., Daniel, M., Gourmel, B., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021129 · Cited by 99
Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia
Hajj, H. E., El-Sabban, M. E., Hasegawa, H., Zaatari, G. S., Ablain, J., Saab, S. T., Janin, A., Mahfouz, R. A., Nasr, R., Kfoury, Y. S., et al. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20101095 · Cited by 98
Ablain, J., Leiva, M., Pérès, L., Fonsart, J., Anthony, E., & de Thé, H. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20122337 · Cited by 96
The Histone Demethylase PHF8 Governs Retinoic Acid Response in Acute Promyelocytic Leukemia
Arteaga, M. F., Mikesch, J., Qiu, J. J., Christensen, J. F., Helin, K., Kogan, S. C., Dong, S., & So, C. W. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.014 · Cited by 90
Kim, Y.-E., & Ahn, J. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004785 · Cited by 88
A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells
Condemine, W., Takahashi, Y., Bras, M. L., et al. (2007) · Journal of Cell Science · doi:10.1242/jcs.007492 · Cited by 88
Forced retinoic acid receptor α homodimers prime mice for APL-like leukemia
Sternsdorf, T., Phan, V. T., Maunakea, M. L., Ocampo, C. B., Sohal, J., Silletto, A., Galimi, F., Beau, M. M. L., Evans, R. M., & Kogan, S. C. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.030 · Cited by 86
ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation
Dassouki, Z., Şahin, U., Hajj, H. E., Jollivet, F., Kfoury, Y. S., Lallemand-Breitenbach, V., Hermine, O., de Thé, H., & Bazarbachi, A. A. (2014) · Blood · doi:10.1182/blood-2014-04-572750 · Cited by 84
Cicconi, L., Divona, M., Ciardi, C., Ottone, T., Ferrantini, A., Lavorgna, S., Alfonso, V., Paoloni, F. P., Piciocchi, A., Avvisati, G., et al. (2016) · Leukemia · doi:10.1038/leu.2016.122 · Cited by 84
Efficace, F., Mandelli, F., Avvisati, G., Cottone, F., Ferrara, F., Bona, E. D., Specchia, G., Breccia, M., Levis, A., Sica, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3453 · Cited by 78
Current standard treatment of adult acute promyelocytic leukaemia
Lo‐Coco, F., Cicconi, L., & Breccia, M. (2015) · British Journal of Haematology · doi:10.1111/bjh.13890 · Cited by 72
Schoofs, T., Rohde, C., Hebestreit, K., Klein, H., Göllner, S., Schulze, I., Lerdrup, M., Dietrich, N., Singh, S. A., Witten, A., et al. (2012) · Blood · doi:10.1182/blood-2012-08-448860 · Cited by 71
PML-RARA–targeted DNA vaccine induces protective immunity in a mouse model of leukemia
Padua, R. A., Larghero, J., Robin, M., Pogam, C. L., Schlageter, M., Muszlak, S., Frič, J., West, R., Rousselot, P. H., Phan, T. H., et al. (2003) · Nature Medicine · doi:10.1038/nm949 · Cited by 70
Zhu, H., Hu, J., Chen, L., Zhou, W., Li, X., Wang, L., Zhao, X., Zhang, Y., Zhao, H., Wang, A., et al. (2016) · Blood · doi:10.1182/blood-2016-02-699439 · Cited by 70
Self-citationTargeted Therapy Alone for Acute Promyelocytic Leukemia
Lo‐Coco, F., Donato, L. D., & Schlenk, R. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1513710 · Cited by 66
Gallagher, R. E., Moser, B. K., Racevskis, J., Poiré, X., Bloomfield, C. D., Carroll, A. J., Ketterling, R. P., Roulston, D., Schachter-Tokarz, E. L., Zhou, D.-C., et al. (2012) · Blood · doi:10.1182/blood-2012-01-407601 · Cited by 61
Akagi, T., Shih, L., Kato, M., Kawamata, N., Yamamoto, G., Sanada, M., Okamoto, R., Miller, C. W., Liang, D., Ogawa, S., et al. (2008) · Blood · doi:10.1182/blood-2007-12-130260 · Cited by 61
Roussel, M. J. S., & Lanotte, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204863 · Cited by 61
Westervelt, P., Pollock, J. L., Oldfather, K. M., Walter, M. J., Ma, M. K., Williams, A. H., DiPersio, J. F., & Ley, T. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132657799 · Cited by 48
Shen, Y., Fu, Y., Zhu, Y., Lou, Y., Gu, Z., Shi, J., Chen, B., Chen, C., Zhu, H., Hu, J., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.04.006 · Cited by 48
Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation
Vitaliano-Prunier, A., Halftermeyer, J., Ablain, J., de Reyniès, A., Pérès, L., Bras, M. L., METZGER, D., & de Thé, H. (2014) · Blood · doi:10.1182/blood-2014-03-561852 · Cited by 46
PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia
Cole, C. B., Verdoni, A. M., Ketkar, S., Leight, E. R., Russler‐Germain, D. A., Westover, T., Demeter, R., Magrini, V. J., & Ley, T. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82897 · Cited by 46
Deacetylation of the tumor suppressor protein PML regulates hydrogen peroxide-induced cell death
Guan, D., Lim, J. H., Peng, L., Liu, Y., Lam, M. C., Seto, E., & Kao, H.-Y. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.185 · Cited by 45
Muto, A., Kizaki, M., Kawamura, C., Matsushita, H., Fukuchi, Y., Umezawa, A., Yamada, T., Hata, J., Hozumi, N., Yamato, K., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402162 · Cited by 42
Lou, Y., Ma, Y., Sun, J., Ye, X., Pan, H., Wang, Y., Qian, W., Meng, H., Mai, W., He, J., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2477-x · Cited by 41
Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia
Quignon, F., Chen, Z., & de Thé, H. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00025-5 · Cited by 41
Self-citationOcchionorelli, M., Santoro, F., Pallavicini, I., Gruszka, A., Moretti, S., Bossi, D., Viale, A., Shing, D. C., Ronzoni, S., Muradore, I., et al. (2011) · Leukemia · doi:10.1038/leu.2011.18 · Cited by 40
Varying responses of PML-RARA with different genetic mutations to arsenic trioxide
Liu, J., Zhu, H., Jiang, H., Jiang, Q., & Huang, X. (2015) · Blood · doi:10.1182/blood-2015-04-637678 · Cited by 36
Mi, J.-Q., Chen, S., Zhou, G., Yan, X., & Chen, Z. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12376 · Cited by 33
Self-citationIaccarino, L., Ottone, T., Divona, M., Cicconi, L., Cairoli, R., Voso, M. T., & Lo‐Coco, F. (2016) · British Journal of Haematology · doi:10.1111/bjh.13910 · Cited by 31
Estey, E. H., Koller, C. A., Tsimberidou, A. M., O'Brien, S. M., Beran, M., Cortes, J. E., Tírado-Gómez, M., Lopez‐Berestein, G., & Kantarjian, H. M. (2005) · Blood · doi:10.1182/blood-2004-09-3437 · Cited by 27
HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia
Mehdipour, P., Santoro, F., Botrugno, O. A., Romanenghi, M., Pagliuca, C., Matthews, G. M., Johnstone, R. W., & Minucci, S. (2017) · Leukemia · doi:10.1038/leu.2017.3 · Cited by 25
Gaillard, C., Tokuyasu, T. A., Rosen, G. P., Sotzen, J. R., Vitaliano-Prunier, A., Roy, R., Passegue, E. A., de Thé, H., Figueroa, M. E., & Kogan, S. C. (2015) · Haematologica · doi:10.3324/haematol.2014.123018 · Cited by 19
Sampi, K., Honma, Y., Hozumi, M., & Sakurai, M. (1985) · Leukemia Research · doi:10.1016/0145-2126(85)90039-6 · Cited by 18
Genomewide array‐based comparative genomic hybridization analysis of acute promyelocytic leukemia
Karnan, S., Tsuzuki, S., Kiyoi, H., Tagawa, H., Ueda, R., Seto, M., & Naoe, T. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20309 · Cited by 15
Koury, L. C. A., Ganser, A., Berliner, N., & Rego, E. M. (2017) · British Journal of Haematology · doi:10.1111/bjh.14589 · Cited by 15
Complete senescence: RB and PML share the task
Vernier, M., & Ferbeyre, G. (2014) · Cell Cycle · doi:10.4161/cc.28090 · Cited by 13
The key role of PML in IFN-α induced cellular senescence of human mesenchymal stromal cells
Fu, S., Wei, J., WANG, G., Wang, B., Wang, Y., Lai, X., & Huang, H. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2738 · Cited by 13
Engaging a senescent response to cure leukemia
Bourdeau, V., & Ferbeyre, G. (2014) · Nature Medicine · doi:10.1038/nm.3469 · Cited by 7
Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?
Ravandi, F., & Kantarjian, H. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00210-7 · Cited by 6
Cited by
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
Differentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
Liquid–liquid phase separation drives cellular function and dysfunction in cancer
Mehta, S., & Zhang, J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00444-7 · Cited by 437
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Metadata
- Authors
- de Thé, H., Pandolfi, P. P., & Chen, Z.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 32
- Issue
- 5
- Pages
- 552-560
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2768202893
- Cited by
- 297
- References
- 125
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.